SARA
LÓPEZ TARRUELLA COBO
Profesora asociada de Ciencias de la Salud
JOSÉ ÁNGEL
GARCÍA SÁENZ
Profesor asociado de Ciencias de la Salud
JOSÉ ÁNGEL GARCÍA SÁENZ-rekin lankidetzan egindako argitalpenak (21)
2024
-
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study
Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172
2023
-
Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab
JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846
2022
-
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
Cancers, Vol. 14, Núm. 3
2021
-
Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
Scientific Reports, Vol. 11, Núm. 1
2019
-
Breast cancer PAM50 signature: Correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series
BMC Genomics, Vol. 20, Núm. 1
-
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Scientific Reports, Vol. 9, Núm. 1
2018
-
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel
Clinical Cancer Research, Vol. 24, Núm. 23, pp. 5820-5829
-
Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification
Clinical Cancer Research, Vol. 24, Núm. 8, pp. 1845-1852
2017
-
Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts
Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657
-
Erratum to: Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial (Breast Cancer Research and Treatment, (2016), 156, 3, (507-515), 10.1007/s10549-016-3792-1)
Breast Cancer Research and Treatment
-
Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
Breast Cancer Research and Treatment, Vol. 162, Núm. 1, pp. 181-189
2016
-
Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial
Breast Cancer Research and Treatment, Vol. 156, Núm. 3, pp. 507-515
-
Review: circulating tumor cells in the practice of breast cancer oncology
Clinical and Translational Oncology, Vol. 18, Núm. 8, pp. 749-759
2013
-
Circulating tumor cells following first chemotherapy cycle: An early and strong predictor of outcome in patients with metastatic breast cancer
Oncologist, Vol. 18, Núm. 8, pp. 917-923
2011
-
Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer
Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136
-
Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review
Clinical and Translational Oncology, Vol. 13, Núm. 2, pp. 121-132
2009
-
Circulating tumor cells in metastatic breast cancer: Timing of blood extraction for analysis
Anticancer Research, Vol. 29, Núm. 10, pp. 4185-4187
2007
-
Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid
Medicina oral, patología oral y cirugía bucal. Ed. inglesa, Vol. 12, Núm. 5, pp. 4
2006
-
Cáncer de próstata
Tiempos médicos: revista de educación médica continuada, Núm. 631, pp. 31-36
-
Significance of the immunohistochemical detection of lymph node micrometastases in Stage II Colorectal Carcinoma
Clinical and Translational Oncology, Vol. 8, Núm. 9, pp. 676-680